Orchard Therapeutics Announces Interim Data for OTL-203 Showing Positive Clinical Results in Multiple Disease Manifestations of Mucopolysaccharidosis Type I Hurler Syndrome (MPS-IH) February 9, 2021
Innovent Announces First Patient Dosed in Phase III Pivotal Trial of IBI310 (CTLA-4) Combined with TYVYT® (sintilimab injection) for the Treatment of First-line Advanced Hepatocellular Carcinoma February 8, 2021
Denali Therapeutics to Present New Data on ETV:IDS (DNL310) for the Potential Treatment of Hunter Syndrome at WORLDSymposium™ February 5, 2021
Orchard Therapeutics Announces $150 Million Strategic Financing Strengthened Financial Position Supports Execution into the First Half of 2023 February 5, 2021
Syngenta Crop Protection and Insilico Medicine to Harness Artificial Intelligence to Transform Sustainable Product Innovation February 3, 2021
Coherus BioSciences to Receive $50 million Strategic Investment from Immuno-Oncology Partner Junshi Biosciences February 2, 2021
VitalCDM® Ranked #1 in KLAS Revenue Cycle, Chargemaster Management Category for Third Year in a Row February 2, 2021